The Compound Group
Volume 01 · Est. 2026

We build the healthcompanies that should exist.Then we quietly acquire the ones that already do.

A consumer biotech media studio. GLP-1 to neuroscience. Supplements to pet health. We build what we'd want to use. We acquire what's already working.

¹Footnoted as in every stat has a source, every methodology is public, every ranking shows our work — the standard we'd want applied to anything we'd use ourselves.
Scroll · Portfolio below
§Portfolio — active and forthcoming
🔒glp1picks.com
The Pricing Index
48 providers · Updated May 2026
Vol. IV
Issue 04
Editor's Top Pick
Eden Health
$249/mo · All-in · No hidden fees
8.9
of 10
02Sprout Health$259/mo8.6
03Strut Health$269/mo8.4
04Sesame Care$189/mo8.2
05Enhance MD$299/mo8.0
Methodology publishedRead the full index →
ILiveBuilt in-house

GLP-1 Picks

A clear-eyed comparison of the major GLP-1 telehealth programs, priced the way a patient actually pays for them.

We review forty-eight GLP-1 telehealth programs on three dimensions: the full monthly cost over a typical year, the quality and credentials of the clinical care, and the transparency of the program's pricing structure. The scoring methodology is published in full, the affiliate relationships are disclosed on every page, and the rankings follow directly from the methodology. When we earn a commission on a visit, the page you're reading says so.

Type
Comparison site
Revenue
Affiliate
Since
2026
Visit glp1picks.com
🔒hrtpicks.com
Prices verified · July 2026
Her HRT · His TRT
The independent
hormone-care comparison.
14 providers · No pay-for-placement
Price Transparency Grade
ABCDF
01Midi HealthA9.1
02AlloyA8.7
03WinonaB8.5
From the team behind GLP-1 PicksSee the rankings →
IILiveBuilt in-house

HRT Picks

The independent hormone-care comparison — verified prices, transparency grades, and a rank no provider can buy.

In November 2025 the FDA removed black-box warnings from six menopausal hormone therapy products; demand doubled within months and the estradiol patch went into nationwide shortage. We compare fourteen hormone telehealth providers across two wings — women's menopause HRT at the front door, men's TRT alongside it — on a five-dimension methodology, and grade every provider's pricing candor from A to F with a Price Transparency Grade no other comparison publishes. Verified prices, affiliate disclosures on every page, no pay-for-placement. The score is methodology-driven; affiliate status never moves the rank.

Type
Comparison site
Revenue
Affiliate
Since
2026
Visit hrtpicks.com
🔒glp1pets.com
Independently verified · April 2026
Cats first · Dogs next
Pet GLP-1 — what's real,
what's coming, what to do now.
The independent tracker for veterinary GLP-1 drugs. Okava's MEOW-1 cat trial reads out summer 2026.
Cats: Where the Science Is →
Dogs: The Honest Status →
From the team behind GLP-1 Picks
IIILiveBuilt in-house

GLP-1 Pets

The first dedicated tracker for veterinary GLP-1 — same methodology as the human-side index, applied to the pet chemistry class.

Sixty-one percent of US cats and fifty-nine percent of US dogs are overweight or obese (APOP). The first pharmaceutical answer is on its way: Okava's MEOW-1 cat trial of an exenatide-releasing implant reads out summer 2026, and Akston Biosciences is running a once-weekly injection at Cornell. Realistic FDA approval for cats is 2027–28, dogs 2028–30. We track every trial milestone, regulatory action, and pricing signal — and tell readers what works today (food, portions, body-condition scoring) until the science lands.

Type
Authority site
Revenue
Affiliate (post-launch)
Since
2026
Visit glp1pets.com
Titrate
Peptide & GLP-1
Reconstitution, doses,
stacks, side effects.
One app. Every unit.
iOS first
Launching 2026
9:41
Monday, April 14
Today's stack
Tirzepatide
5.0 mg
Due today · Left abdomen
BPC-157
250 mcg
✓ Logged
M
T
W
T
F
S
S
Reconstitution
10 mg vial · 2 mL BAC · 0.25 mL per 1.25 mg
Weight
184.2lb
−12.4
IVLiveBuilt in-house

Titrate

A peptide and GLP-1 tracker built around the decisions a patient keeps making — dose, reconstitution, stack, refill, program.

The core logging works the way these apps should: doses, weight trends, side effects, injection-site rotation. The decision-support layer is where Titrate departs from the category. Reconstitution calculators with a unit toggle the category has been missing. Multi-compound stacking past the three-peptide ceiling most apps cap at. And as programs update their pricing structures, formularies, and dose-escalation policies, the app surfaces the ones that continue to fit your situation — so the next refill is a deliberate choice. Now shipping on the App Store; the marketing site at titrate.health is the way in.

Type
iOS app
Revenue
Subscription + affiliate
Since
May 2026
Visit titrate.health
🔒bestpeptideforthat.com
Verified · July 2026
Evidence over hype
Every peptide,
graded by the evidence.
46 peptides · Cited to primary sources
Evidence Grade
ABCDF
01TesamorelinAHuman RCTs
02SermorelinBHuman data
03BPC-157DAnimal only
From the team behind GLP-1 PicksSee the evidence →
VLiveBuilt in-house

Best Peptide For That

Every research peptide, graded A to F by the strength of actual human evidence, and honest about what is legal.

Peptide therapy sits in a regulatory transition, and most of what sells online is gray-market with animal-only evidence. We grade forty-six research peptides, from BPC-157 and TB-500 to the GLP-1 medications, tesamorelin and PT-141, on an A to F scale set by the strength of published human proof, alongside a plain account of each compound's legal status and the July 2026 FDA advisory vote that decides which become legally compoundable. Every claim is cited to a primary source, and we never point anyone to gray-market sourcing. The grade follows the evidence, not the affiliate.

Type
Evidence index
Revenue
Affiliate (post-launch)
Since
2026
Visit bestpeptideforthat.com
🔒revolume.app
RevolumeA Compound product
For Ozempic · Wegovy · Mounjaro · Zepbound
You lost the weight.
Don't lose your face.
Track facial volume changes on GLP-1. 15 skin markers in 60 seconds.
Join the waitlist
ComingiPhone
Cited: Vanderbilt Facial Volume Study, JCD 2026, ASDS.
Cheek volume
Jawline laxity
15 markers
VIIn developmentBuilt in-house

Revolume

The skin scan built for GLP-1 — because the weight comes off, and the face follows.

Sixty-five percent of patients on semaglutide, tirzepatide, or compounded GLP-1s experience facial volume loss within their first six months on the medication. Revolume is a private, on-device skin scan that measures the fifteen markers specific to post-rapid-weight-loss skin — volume, jawline definition, nasolabial depth, laxity — and routes the user to the routine, the telehealth prescription, or the in-clinic procedure that actually fits the stage they're at.

Type
Web scan + iOS app
Revenue
Affiliate + procedure referral
Launch
2026
Visit revolume.app
§§What comes next

Adjacent categories, where the same research methodology transfers and the consumer is asking the same three questions.

What does it cost over the course of a year, what is actually in it, and what is the evidence that it does what the packaging says. We build or acquire where those three questions have no clear answer yet.

  • 06
    Supplement Index
    A reviews site for the supplements GLP-1 and HRT users tend to look for — protein, fiber, electrolytes, micronutrient support, plus the menopause-specific category (Estroven, Amberen, Wile). Sourced from peer-reviewed evidence where it exists; the methodology notes where the research is still thin.
    Adjacent category2026
  • 07
    Neuroscience Index
    The supplement side of cognition — nootropics, neuroprotective compounds, cognitive-aging formulas — reviewed with the same rigor we apply to GLP-1. Less about optimization culture, more about what has clinical trials behind it and what is still essentially hopeful biochemistry.
    Cognitive supplements2027
  • 08
    Neuroplasticity Lab
    The behavioral counterpart to the Neuroscience Index. Rather than what goes into the brain, this asks how the brain can actually be trained — through cognitive apps, neurofeedback hardware, meditation platforms, and the small protocols with measurable effects. A separate product, sharing the same research discipline.
    Training & tools2027
◉The map · How the properties connect

A portfolio is a graph. This is where the edges are.

Each circle is a product or a public asset the studio maintains. The edges describe audience overlap, shared methodology, or infrastructure that recurs across categories. Hover a node to trace its relationships — or grab one and rearrange the map yourself.

Hover or tap a node
ParentLive productIn developmentPlannedPublic resourceAudience feedShared resource

Four properties are live, one more in development. Four more come online across 2026 and 2027. As they do, the graph densifies — a shared methodology, shared datasets, and an audience that overlaps more than any one product suggests on its own. The compounding, when it works, lives in the edges — in how the nodes connect.

Where we stand, as of April
0+
Pages published
Each tied to its sources
0
Providers reviewed
Scored on all-in monthly cost
0
State-level guides
Including Medicaid coverage detail
0
Affiliate partners
Disclosed on every relevant page
‡Pricing data · From our April index

Advertised starter price, plotted against actual ongoing monthly cost.

Each dot represents a GLP-1 telehealth program in our index. The dashed diagonal marks the point where the starter rate and the typical ongoing rate are the same. Programs above the line have a pricing structure — an introductory month, a separately billed membership, dose-based escalation — that makes their first-month cost different from their steady-state cost. Hover a dot for the specifics.

Ongoing monthly cost ↑
$50$150$250$350
$350$250$150$50
Advertised starter price →
Flat pricing — starter matches ongoingStructured pricing — starter differs from ongoingParity line
Programs in the index
16
Sampled from the forty-eight-program index on glp1picks.com
Flat pricing
7
Starter price matches the ongoing monthly rate
Average variance
+$84
Typical difference between starter and ongoing, across the set
Widest structural variance
Ro +$245
A program where introductory-month pricing differs most from the steady-state monthly rate. The structural distance between the two numbers, measured in dollars per month.
ΩHow we operate

Research has a shape. This is how ours gets organized.

●Published methodology
●Named medical reviewers
●Disclosed affiliate relationships
●Versioned recommendations
●Peer-reviewed sources
●Verified pharmacy licenses
●Audited side-effect data
●Tracked ongoing pricing
●Pet-health research
●Mapped search intent
●Quarterly content review
●Public changelog
●Published methodology
●Named medical reviewers
●Disclosed affiliate relationships
●Versioned recommendations
●Peer-reviewed sources
●Verified pharmacy licenses
●Audited side-effect data
●Tracked ongoing pricing
●Pet-health research
●Mapped search intent
●Quarterly content review
●Public changelog
01Pillar · databases

Databases

Every ranking is grounded in data we maintain ourselves, audited on a weekly cycle.

Pricing, dosing schedules, FDA alerts, state-level Medicaid coverage, and the terms of our affiliate partnerships all live in structured datasets that are audited each week. The numbers on the page are the numbers in the database, and when something shifts — a new formulation, a revised policy, a price change — the process catches it within days.

12,400+
Datapoints in structured databases, refreshed weekly
✧Intelligence layer

Research is the whole game.

Barque is the protocol we lean on for it. Curiosity paired with a dataset far larger than any one mind can hold — cross-signal fusion, five-agent scenarios, Brier-scored forecasts. It tells us what to build, what to skip, and when the window opens.

Informs every page at GLP-1 Picks, every feature in GLP-1 Tracker, and the next verticals we're scouting.

Backtests resolved
4
4 of 4 direction-correct
Average Brier score
0.066
Lower is better · below 0.10 is strong calibration
Live forecasts
5
Currently pending, with public resolution dates
❝From our methodology
Show the work, and keep showing it — as the evidence changes, so should the conclusion.
†Operating principles

We started by asking ourselves the same questions the sites now answer. What does a GLP-1 program actually cost over a year of use. Which supplements have real research behind them. How dose escalation works in practice, not in the marketing copy.

The answers took more work than we expected. So we kept the notes. The notes became databases. The databases became sites.

Research before opinion. Methodology before recommendation. Infrastructure that compounds across categories. The work is the work.

Four commitments

The four operating constraints each property in the portfolio is built around, regardless of category or stage.

Crystalline molecular network rendered in warm light

Research · Structured and maintained

I
Transparency

The scoring methodology for every ranking is published in detail on every site we run. Every affiliate relationship is disclosed on the pages where it's relevant. And we report pricing as the ongoing monthly cost a typical patient pays over a full year of use — the number that matters once the introductory period ends.

II
Specificity

Our content names the specific program, quotes the specific cost, and describes the specific trade-off — which is what lets a reader actually weigh one option against another. The reader who comes back for the next question is worth more than a reader who clicks once on a generic superlative.

III
Compounding

Each property in the portfolio extends the same research discipline into an adjacent category. The audience that trusts our GLP-1 work is the same audience looking for supplement guidance. The database infrastructure built for one transfers directly to the next. Pet health broadens the methodology to a parallel customer base; the neuroscience work reads to a different reader entirely. The underlying process travels.

IV
Patience

We build for ten years — content that ages well, data that's audited continuously, partner relationships that hold. If an acquisition is part of the story, it's because the work stands up to scrutiny the way we'd want our own work scrutinized.